ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >NELFINAVIR

NELFINAVIR

NELFINAVIR Structure
CAS No.
159989-64-7
Chemical Name:
NELFINAVIR
Synonyms
AG 1341;nefinavir;NELFINAVIR;NELFINAVIR-12;Nelfinavir D5;8a-beta))-a-bet;NELFINAVIR iMpurity;NELFINAVIR USP/EP/BP;Nelfinavir (AG-1341);Nelfinavir Regeoisomer
CBNumber:
CB8213806
Molecular Formula:
C32H45N3O4S
Molecular Weight:
567.78
MOL File:
159989-64-7.mol
MSDS File:
SDS
Modify Date:
2024/7/2 8:55:18

NELFINAVIR Properties

Melting point 185-186 °C
Boiling point 786.8±60.0 °C(Predicted)
alpha D -119.23° (c = 0.26 in methanol)
Density 1.22±0.1 g/cm3(Predicted)
storage temp. under inert gas (nitrogen or Argon) at 2–8 °C
solubility ≥ 20.45mg/mL in Ethanol
form Powder
pka pKa1 6.0; pKa2 11.06(at 25℃)
color White to off-white
Water Solubility 7g/L(temperature not stated)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302
Precautionary statements  P501-P270-P264-P301+P312+P330
Toxicity rat,LD,oral,> 5gm/kg (5000mg/kg),Toxicologist. Vol. 42, Pg. 55, 1998.

NELFINAVIR Chemical Properties,Uses,Production

Uses

Antiviral.

Indications

Nelfinavir (Viracept) is probably the most commonly used protease inhibitor because of its low incidence of serious adverse effects. Its most common side effects are diarrhea and flatulence; these may resolve with continued use. In addition to the drugs contraindicated for use with all protease inhibitors, amiodarone, rifampin, and quinidine are contraindicated in patients taking nelfinavir.

Definition

ChEBI: An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.

Antimicrobial activity

Nelfinavir inhibits HIV-1 and HIV-2 proteases. Bioavailability is affected to only a limited degree by combination with lowdose ritonavir.

Acquired resistance

Resistance is most frequently selected through a D30N mutation in the HIV protease. An L90M mutation also confers resistance.

Pharmaceutical Applications

A synthetic chemical formulated as the mesylate for oral administration.

Pharmacokinetics

Oral absorption: c. 70–80% (with food)
Cmax 750 mg thrice daily: c. 3–4 mg/L
1250 mg twice daily: c. 4 mg/L
Cmin 750 mg thrice daily: c. 1–3 mg/L
1250 mg twice daily: c. 0.7–2.2 mg/L
Plasma half-life: c. 3.5 h
Volume of distribution: c. 2–7 L/kg
Plasma protein binding: >98%
Absorption and distribution
Food improves the bioavailability and the drug should be administered with a light meal. The semen:plasma ratio is 0.07. It is distributed into breast milk.
Metabolism and excretion
One major and several minor oxidative metabolites are found in plasma. Most of an oral dose is recovered in feces as unchanged drug (22%) and metabolites (78%). The remainder is recovered in urine, mainly unchanged.
An increase in the area under the time–concentration curve (AUC) has been observed in patients with hepatic impairment, but specific dose recommendations have not been made.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Side effects

The most common adverse effect is diarrhea of mild to moderate severity. Other side effects include nausea, fatigue, vomiting and headache. It is associated with less dyslipidemia in comparison with ritonavir-boosted protease inhibitors.

Metabolism

Following oral administration, nelfinavir peak levels in plasma ranged from 0.34 mg/mL (10 mg/kg in the dog) to 1.7 mg/mL (50 mg/kg in the rat). In the dog, nelfinavir was slowly absorbed, and bioavailability was 47%. The drug appeared to be metabolized in the liver, and the major excretory route was in feces.

NELFINAVIR Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 101)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
CONIER CHEM AND PHARMA LIMITED +8618523575427 China 49391 58 Inquiry
Career Henan Chemica Co +86-0371-86658258 +8613203830695 China 30253 58 Inquiry
Dideu Industries Group Limited +86-29-89586680 +86-15129568250 China 26216 58 Inquiry
AFINE CHEMICALS LIMITED +86-0571-85134551 China 15395 58 Inquiry
Sinoway Industrial co., ltd. 0592-5800732; +8613806035118 China 992 58 Inquiry
Nextpeptide Inc +86-0571-81612335 +8613336028439 China 19915 58 Inquiry
InvivoChem +1-708-310-1919 +1-13798911105 United States 6393 58 Inquiry

Related articles

  • Uses and side effects of Nelfinavir
  • Nelfinavir is used primarily for the treatment of HIV-1 infection, but has also been recently used in patients with malignancy....
  • Apr 1,2022

NELFINAVIR Spectrum

3-isoquinolinecarboxamide,n-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hy 8a-beta))-a-bet nefinavir NELFINAVIR (3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide Nelfinavir & Nelfinavir Mesylate AG 1341 NELFINAVIR-12 Nelfinavir Regeoisomer N-tert-butyl-2-[2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide AG 1341; AG-1341; AG1341 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- NELFINAVIR USP/EP/BP (3S,4aS,8aS)-N-(tert-Butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide Nelfinavir (AG-1341) Nelfinavir D5 NELFINAVIR iMpurity 159989-64-7 C32H45N3O4SCH4O3S C32H45N3O4SC32H45N3O4SCH3SO3H peptides